Range and Consistency of Infection Outcomes Reported in Trials Conducted in Kidney Transplant Recipients: A Systematic Review.
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
01 12 2021
01 12 2021
Historique:
pubmed:
4
3
2021
medline:
30
3
2022
entrez:
3
3
2021
Statut:
ppublish
Résumé
Infection remains a leading cause of death in kidney transplant recipients. This study aimed to assess the scope and consistency of infection outcomes reported in contemporary trials conducted in kidney transplant recipients. A literature review of all randomized trials and trial protocols reporting infection outcomes in adult kidney transplant recipients was identified in the Cochrane Kidney and Transplant Specialized Register from January 2014 to July 2019. Characteristics and infection outcomes from the trials were analyzed. From 102 included trials, 772 outcome measures were extracted and categorized into 216 unique measures with a median of 3.2 outcome measures per trial (range: 1-9). Measures were further grouped into 32 outcomes based on site of infection (14 outcomes) and organism (18 outcomes). The most commonly reported site-specific outcome and organism-specific outcome were systemic infection (71% trials) and cytomegalovirus infection (62% trials), respectively. Outcome metric and methods of aggregation included mean, median, proportion, proportional change, and number of patients with at least 1 episode. Across all trials, measures were assessed at 55 different time points with a range of 1-11 time points per trial. Infection outcomes in kidney transplant recipients were frequently reported by site and organism but varied widely in terms of outcome, metrics, method of aggregation, and time point of measurement. Establishment of core outcomes for infection based on the shared priorities of patients/caregivers and health professionals may improve the consistency, comparability, and usefulness of trial evidence.
Sections du résumé
BACKGROUND
Infection remains a leading cause of death in kidney transplant recipients. This study aimed to assess the scope and consistency of infection outcomes reported in contemporary trials conducted in kidney transplant recipients.
METHODS
A literature review of all randomized trials and trial protocols reporting infection outcomes in adult kidney transplant recipients was identified in the Cochrane Kidney and Transplant Specialized Register from January 2014 to July 2019. Characteristics and infection outcomes from the trials were analyzed.
RESULTS
From 102 included trials, 772 outcome measures were extracted and categorized into 216 unique measures with a median of 3.2 outcome measures per trial (range: 1-9). Measures were further grouped into 32 outcomes based on site of infection (14 outcomes) and organism (18 outcomes). The most commonly reported site-specific outcome and organism-specific outcome were systemic infection (71% trials) and cytomegalovirus infection (62% trials), respectively. Outcome metric and methods of aggregation included mean, median, proportion, proportional change, and number of patients with at least 1 episode. Across all trials, measures were assessed at 55 different time points with a range of 1-11 time points per trial.
CONCLUSIONS
Infection outcomes in kidney transplant recipients were frequently reported by site and organism but varied widely in terms of outcome, metrics, method of aggregation, and time point of measurement. Establishment of core outcomes for infection based on the shared priorities of patients/caregivers and health professionals may improve the consistency, comparability, and usefulness of trial evidence.
Identifiants
pubmed: 33653998
doi: 10.1097/TP.0000000000003723
pii: 00007890-202112000-00036
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2632-2638Subventions
Organisme : NIDDK NIH HHS
ID : U01 DK116042
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK102981
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
S.C. is supported by the Australian National Health and Medical Research Council (NHMRC) Postgraduate Scholarship, the Microba recipient grant, the Metro South Research Support Scheme, and the Royal Australasian College of Physicians (RACP) Jacquot NHMRC Research Excellence top-up award. E.A. is supported by a NHMRC Postgraduate Scholarship and RACP Jacquot NHMRC Award for Excellence. C.M.H. is the recipient of research grants paid to her institution from Baxter Healthcare and Fresenius Medical Care and from Otsuka, Janssen, and GlaxoSmithKline for trial steering committee activities, paid to her institution. D.W.J. has received consultancy fees, research grants, speaker’s honoraria, and travel sponsorships from Baxter Healthcare and Fresenius Medical Care. He has received consultancy fees from Astra Zeneca and AWAK, speaker’s honoraria from Ono, and travel sponsorships from Amgen. He is a current recipient of an Australian NHMRC Practitioner Fellowship. N.M.I. has received consultancy fees and speakers honoraria from Alexion Pharmaceuticals, Novo Nordisk, and Amgen. A.T. is supported by the NHMRC Research Fellowship. A.K.V. receives grant support from the Royal Australasian College of Physicians (Jacquot Research Establishment Award) and the Princess Alexandra Research Foundation. D.B. receives institutional research grant funding from CareDx, speaking honoraria from CareDx and Veloxis and is a consultant for AlloVir, Amplyx, Argenyx, CareDx, Medeor, Natera, Sanofi, and Veloxis. D.B. is supported by NIDDK U01 DK116042-01 and R01DK102981. The other authors declare no conflicts of interest.
Références
Fishman JA. Infection in organ transplantation. Am J Transplant. 2017;17:856–879.
Chan S, Pascoe EM, Clayton PA, et al. Infection-Related Mortality in Recipients of a Kidney Transplant in Australia and New Zealand. Clin J Am Soc Nephrol. 2019;14:1484–1492.
Sousa SRd, Galante NZ, Barbosa DA, et al. Incidência e fatores de risco para complicações infecciosas no primeiro ano após o transplante renal. J Bras Nefrol. 2010;32:77–84.
Kumar MS, Cridge P, Molavi A, et al. Infectious complications in the first 100 days after renal transplantation. Transplant Proc. 1995;27:2705–2706.
Alangaden GJ, Thyagarajan R, Gruber SA, et al. Infectious complications after kidney transplantation: current epidemiology and associated risk factors. Clin Transplant. 2006;20:401–409.
Pourmand G, Salem S, Mehrsai A, et al. Infectious complications after kidney transplantation: a single-center experience. Trans Infect Dis. 2007;9:302–309.
Tong A, Gill J, Budde K, et al.; SONG-Tx Investigators. Toward establishing core outcome domains for trials in kidney transplantation: report of the Standardized Outcomes in Nephrology-kidney transplantation consensus workshops. Transplantation. 2017;101:1887–1896.
Sautenet B, Tong A, Manera KE, et al. Developing consensus-based priority outcome domains for trials in kidney transplantation: a multinational Delphi survey with patients, caregivers, and health professionals. Transplantation. 2017;101:1875–1886.
Tong A, Manns B, Wang AYM, et al.; SONG Implementation Workshop Investigators. Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop. Kidney Int. 2018;94:1053–1068.
Sautenet B, Tong A, Chapman JR, et al. Range and consistency of outcomes reported in randomized trials conducted in kidney transplant recipients: a systematic review. Transplantation. 2018;102:2065–2071.
Zarin DA, Tse T, Williams RJ, et al. The ClinicalTrials.gov results database — update and key issues. N Eng J Med. 2011;364:852–860.
Centers for Disease Control and Prevention. Surgical Site Infection (SSI) Event; 2017. Centers for Disease Control and Prevention; 2019.
Viecelli AK, O’Lone E, Sautenet B, et al. Vascular access outcomes reported in maintenance hemodialysis trials: a systematic review. Am J Kidney Dis. 2018;71:382–391.
Sahlawi MA, Wilson G, Stallard B, et al. Peritoneal dialysis-associated peritonitis outcomes reported in trials and observational studies: a systematic review. Perit Dial Int. 2020;40:132–140.
Viecelli AK, Howell M, Tong A, et al. Identifying critically important vascular access outcomes for trials in haemodialysis: an international survey with patients, caregivers and health professionals. Nephrol Dial Transplant. 2020;35:657–668.
Viecelli AK, Tong A, O’Lone E, et al.; SONG-HD Vascular Access Workshop Investigators. Report of the Standardized Outcomes in Nephrology-hemodialysis (SONG-HD) consensus workshop on establishing a core outcome measure for hemodialysis vascular access. Am J Kidney Dis. 2018;71:690–700.
Manera KE, Johnson DW, Craig JC, et al. Patient and caregiver priorities for outcomes in peritoneal dialysis: multinational nominal group technique study. Clin J Am Soc Nephrol. 2019;14:74–83.
Owers DS, Webster AC, Strippoli GFM, et al. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2013;2013:CD005133.
Humar A, Michaels M; AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant. 2006;6:262–274.
Ljungman P, Boeckh M, Hirsch HH, et al.; Disease Definitions Working Group of the Cytomegalovirus Drug Development Forum. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017;64:87–91.
Prinsen CA, Vohra S, Rose MR, et al. Core outcome measures in effectiveness trials (COMET) initiative: protocol for an international Delphi study to achieve consensus on how to select outcome measurement instruments for outcomes included in a ‘core outcome set’. Trials. 2014;15:247.